Bolt Biotherapeutics (NASDAQ:BOLT) Stock Passes Below 200-Day Moving Average – Here’s Why

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.63. Bolt Biotherapeutics shares last traded at $0.64, with a volume of 137,236 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Thursday, August 15th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics currently has an average rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Stock Performance

The firm has a market capitalization of $24.31 million, a P/E ratio of -0.38 and a beta of 0.93. The company’s 50 day moving average is $0.65 and its 200-day moving average is $0.80. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative return on equity of 61.40% and a negative net margin of 592.57%. The company had revenue of $1.28 million for the quarter, compared to the consensus estimate of $1.19 million. As a group, equities analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Acuitas Investments LLC raised its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 21.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 630,507 shares of the company’s stock after purchasing an additional 112,555 shares during the quarter. Acuitas Investments LLC owned 1.65% of Bolt Biotherapeutics worth $473,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.